Laboratory study of blood coagulation and the effect of fibrinogen in severe illness

In vitro inflammatory and thrombotic effects of fibrinogen variants - IVIT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58114

Enrollment

Registered

2025-07-30

Start date

2026-01-12

Completion date

Unknown

Last updated

2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

disseminated intravascular coagulation (DIC) blood coagulation disorder in critical illness

Interventions

None.

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Male, aged 18-35 years

Exclusion criteria

Exclusion criteria: - Participation in a scientific intervention study in the last 3 months - No informed consent - History of coagulation disorders- Active use of prescription medication- Use of anticoagulant medication, including aspirin- History of liver disease - History of chronic transmittable disease- History of alcohol, smoking or drug abuse

Design outcomes

Primary

Measure	Time frame
Clot formation (fibrin network assessed with microscopy and quantitatively with ROTEM), inflammation parameters and NETosis markers (quantitatively).	—

Secondary

Measure	Time frame
N/a.	—

Countries

Netherlands

Contacts

Public ContactD. Taha

Erasmus MC, Universitair Medisch Centrum Rotterdam

d.taha@erasmusmc.nl0107038833

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Mar 14, 2026